Mersana Therapeutics, Inc. (MRSN)
NASDAQ$0.4619+0.01 (2.23%)
Market Cap
$55.85M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
718 of 924
Rank in Industry
410 of 527
Insider Buys Sum
Cluster
Trading
Trading
Insider Buys
Quantity
Quantity
Historical
Profitability
Profitability
Investor
Ownership
Ownership
Largest Insider Buys in Sector
MRSN Insider Trading Activity
MRSN Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $0 | 0 | 0 |
Sells | $268,490 | 30 | 100 |
Related Transactions
| Protopapas Anna | director | 0 | $0 | 3 | $16,522 | $-16,522 |
| Mandelia Ashish | VP, Chief Accounting Officer | 0 | $0 | 5 | $20,152 | $-20,152 |
| Carvajal Alejandra | SVP, Chief Legal Officer | 0 | $0 | 5 | $32,903 | $-32,903 |
| Lowinger Timothy B | SVP, Chief Sci.&Tech. Officer | 0 | $0 | 5 | $35,247 | $-35,247 |
| DeSchuytner Brian | SVP, COO & CFO | 0 | $0 | 5 | $35,982 | $-35,982 |
| Bala Mohan | SVP, Chief Development Officer | 0 | $0 | 5 | $36,321 | $-36,321 |
| Huber Martin H. Jr. | President, CEO | 0 | $0 | 2 | $91,363 | $-91,363 |
About Mersana Therapeutics, Inc.
Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen development candidate. It has a strategic research and development partnerships with Merck KGaA and Asana …
Insider Activity of Mersana Therapeutics, Inc.
Over the last 12 months, insiders at Mersana Therapeutics, Inc. have bought $0 and sold $268,490 worth of Mersana Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Mersana Therapeutics, Inc. have bought $33M and sold $1.2M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 14,760 shares for transaction amount of $47,182 was made by Hack Andrew A. F. () on 2022‑05‑31.
List of Insider Buy and Sell Transactions, Mersana Therapeutics, Inc.
| 2025-01-16 | Sale | Lowinger Timothy B | SVP, Chief Sci.&Tech. Officer | 8,048 0.0065% | $0.58 | $4,668 | -8.69% | |
| 2025-01-16 | Sale | Protopapas Anna | director | 8,637 0.007% | $0.58 | $5,009 | -8.69% | |
| 2025-01-16 | Sale | Huber Martin H. Jr. | President, CEO | 4,514 0.0037% | $0.58 | $2,618 | -8.69% | |
| 2025-01-16 | Sale | DeSchuytner Brian | SVP, COO & CFO | 8,470 0.0069% | $0.58 | $4,913 | -8.69% | |
| 2025-01-16 | Sale | Carvajal Alejandra | SVP, Chief Legal Officer | 5,096 0.0041% | $0.58 | $2,956 | -8.69% | |
| 2025-01-16 | Sale | Bala Mohan | SVP, Chief Development Officer | 5,939 0.0048% | $0.58 | $3,445 | -8.69% | |
| 2025-01-16 | Sale | Mandelia Ashish | VP, Chief Accounting Officer | 3,554 0.0029% | $0.58 | $2,061 | -8.69% | |
| 2025-01-15 | Sale | Lowinger Timothy B | SVP, Chief Sci.&Tech. Officer | 1,794 0.0015% | $0.63 | $1,130 | -11.73% | |
| 2025-01-15 | Sale | Protopapas Anna | director | 6,191 0.0051% | $0.63 | $3,900 | -11.73% | |
| 2025-01-15 | Sale | DeSchuytner Brian | SVP, COO & CFO | 2,331 0.0019% | $0.63 | $1,469 | -11.73% | |
| 2025-01-15 | Sale | Carvajal Alejandra | SVP, Chief Legal Officer | 952 0.0008% | $0.63 | $600 | -11.73% | |
| 2025-01-15 | Sale | Mandelia Ashish | VP, Chief Accounting Officer | 1,791 0.0015% | $0.63 | $1,128 | -11.73% | |
| 2025-01-14 | Sale | Lowinger Timothy B | SVP, Chief Sci.&Tech. Officer | 3,483 0.003% | $0.66 | $2,299 | -9.51% | |
| 2025-01-14 | Sale | Protopapas Anna | director | 11,534 0.01% | $0.66 | $7,612 | -9.51% | |
| 2025-01-14 | Sale | DeSchuytner Brian | SVP, COO & CFO | 3,713 0.0032% | $0.66 | $2,451 | -9.51% | |
| 2025-01-14 | Sale | Carvajal Alejandra | SVP, Chief Legal Officer | 3,330 0.0029% | $0.66 | $2,198 | -9.51% | |
| 2025-01-14 | Sale | Bala Mohan | SVP, Chief Development Officer | 3,253 0.0028% | $0.66 | $2,147 | -9.51% | |
| 2025-01-14 | Sale | Mandelia Ashish | VP, Chief Accounting Officer | 1,007 0.0009% | $0.66 | $665 | -9.51% | |
| 2024-10-28 | Sale | Bala Mohan | SVP, Chief Development Officer | 1,884 0.0014% | $1.90 | $3,580 | -32.35% | |
| 2024-10-03 | Sale | Lowinger Timothy B | SVP, Chief Sci.&Tech. Officer | 5,598 0.0048% | $1.96 | $10,972 | -19.80% |
Total: 119
*Gray background shows transactions not older than one year
Insider Historical Profitability
33.04%
| Mandelia Ashish | VP, Chief Accounting Officer | 57519 0.0462% | $25,774.26 | 1 | 12 | <0.0001% |
| New Enterprise Associates 14, L.P. | 10 percent owner | 11959520 9.5959% | $5.36M | 2 | 1 | +8.86% |
| Hack Andrew A. F. | 8663673 6.9515% | $3.88M | 17 | 0 | +48.09% | |
| BARRIS PETER J | 10 percent owner | 8140138 6.5314% | $3.65M | 1 | 0 | +20.77% |
| BARRETT M JAMES | 10 percent owner | 8140138 6.5314% | $3.65M | 1 | 0 | +20.77% |
*Gray background shows insiders who have made transactions during last year
Historical Insider Profitability vs. Competitors
$81,638,324 | 48 | 7.58% | $53.53M | |
$6,787,959 | 35 | 49.84% | $61.7M | |
Mersana Therapeutics, Inc. (MRSN) | $459,011,221 | 33 | 33.04% | $55.85M |
$2,239,226 | 28 | 3.41% | $62.04M | |
$18,274,594 | 22 | -26.07% | $47.82M |
MRSN Institutional Investors: Active Positions
| Increased Positions | 62 | +44.93% | 15M | +13.19% |
| Decreased Positions | 54 | -39.13% | 23M | -20.2% |
| New Positions | 30 | New | 12M | New |
| Sold Out Positions | 13 | Sold Out | 2M | Sold Out |
| Total Postitions | 146 | +5.8% | 107M | -7.02% |
MRSN Ownership Change vs Market
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
| Nextech Invest Ltd. | $6,311.00 | 9.73% | 12.07M | 0 | 0% | 2024-12-31 |
| Ecor1 Capital, Llc | $5,925.00 | 9.14% | 11.33M | -8M | -41.5% | 2024-12-31 |
| Vr Adviser, Llc | $5,365.00 | 8.27% | 10.26M | -1M | -9.45% | 2024-12-31 |
| Blackrock, Inc. | $4,814.00 | 7.42% | 9.21M | +583,321 | +6.77% | 2024-12-31 |
| Bain Capital Life Sciences Investors, Llc | $4,531.00 | 6.99% | 8.66M | 0 | 0% | 2024-12-31 |
| Vanguard Group Inc | $3,691.00 | 5.69% | 7.06M | -119,942 | -1.67% | 2024-12-31 |
| Novo Holdings A/S | $2,223.00 | 3.43% | 4.25M | +4M | New | 2024-12-31 |
| Rock Springs Capital Management Lp | $1,795.00 | 2.77% | 3.43M | +384,902 | +12.63% | 2024-12-31 |
| State Street Corp | $1,446.00 | 2.23% | 2.76M | +39,501 | +1.45% | 2024-12-31 |
| Boxer Capital Management, Llc | $1,378.00 | 2.13% | 2.63M | +3M | New | 2024-12-31 |
Financial Ratios
Summary
Comparison with Competitors
Analyst Recommendations
Analyst Price Targets
Screener Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny StocksPrismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.